Agonist and antagonist actions of antipsychotic agents at 5-HT(1A) receptors: A [35S]GTPγS binding study

European Journal of Pharmacology

Volumn 355, Issue 2-3, 1998, Pages 245-256

  Newman Tancredi, Adrian ^a   Gavaudan, Samantha ^a   Conte, Caroline ^a   Chaput, Christine ^a   Touzard, Manuelle ^a   Verrièle, Laurence ^a   Audinot, Valerie ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT(1A) receptor; 35S GTP S binding; Clozapine; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 (7 METHOXY 1 NAPHTHYL) 4 [2 (2 THENOYLAMINO)ETHYL]PIPERAZINE; 1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; BUSPIRONE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLESINOXAN; GUANINE NUCLEOTIDE BINDING PROTEIN; IPSAPIRONE; METITEPINE; NEUROLEPTIC AGENT; OCAPERIDONE; OLANZAPINE; PIMOZIDE; QUETIAPINE; RACLOPRIDE; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SERTINDOLE; SPIPERONE; TANDOSPIRONE; TIOSPIRONE; UNINDEXED DRUG; ZALOSPIRONE; ZIPRASIDONE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CRICETINAE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGENTS; SULFUR RADIOISOTOPES;

EID: 0031698286     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00483-X     Document Type: Article

References (81)

1. Andersen, H.L., Kilpatrick, I.C., 1995. Prevention by (±)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. Br. J. Pharmacol. 118, 421-427.
2. 1A receptor antagonist (S)UH 301 blocks (R)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat. J. Neural Transm. Gen. Sect. 96, 179-186.
3. 4 sites. Eur. Neuropsychopharmacol. 5, 4-13.
4. Baldessarini, R.J., 1996. Drugs and the treatment of psychiatric disorders. In: Hardman, J.G., Limbird, L.E. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, pp. 399-430.
5. 2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 269, 11687-11690.
6. 1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 35, 1645-1646.
7. 1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)-tetralin: inhibition of (R)-8-hydroxy-2-(dipropyl amino)-tetralin-induced effects. J. Pharmacol. Exp. Ther. 258, 58-65.
8. Boess, F.G., Martin, I.L., 1994. Molecular biology of 5-HT receptors. Neuropharmacology 33, 275-317.
9. Buhot, M.-C., 1997. Serotonin receptors in cognitive behaviors. Current Opinion in Neurobiology 7, 243-254.
10. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30, 565-574.
11. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P., Wong, D.T., 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
12. 3H]8-OH-DPAT) binding. J. Pharmacol. Exp. Ther. 266, 618-625.
13. Clark, M.L., Paredes, A., Costiloe, J.P., Wood, F., 1977. Evaluation of butaclamol in chronic schizophrenic patients. J. Clin. Pharmacol. 17, 529-536.
14. 1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J. Pharmacol. Exp. Ther. 277, 1259-1266.
15. Corbett, R., Hartman, H., Kerman, L.L., Woods, A.T., Strupczewski, J.T., Helsey, G.C., Conway, P.C., Dunn, R.W., 1993. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav. 45, 9-17.
16. 1A receptors that are negatively coupled to adenylate cyclase. Mol. Pharmacol. 39, 780-787.
17. 1A agonists. Synapse 14, 297-304.
18. De Lean, A., Kilpatrick, B.F., Caron, M.G., 1982. Dopamine receptor of the porcine anterior pituitary gland: evidence for two affinity states discriminated by both agonists and antagonists. Mol. Pharmacol. 22, 290-297.
19. 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J. Pharmacol. Exp. Ther. 238, 248-253.
20. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121, 1-26.
21. 1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol. Pharmacol. 33, 178-186.
22. 1A receptor antagonist activity of WAY-100135 and spiperone. J. Pharmacol. Exp. Ther. 268, 441-447.
23. 1A receptor. J. Biol. Chem. 264, 14848-14852.
24. i protein. Cell. Signal. 3, 547-557.
25. Fleischhacker, W.W., Hummer, M., 1997. Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 53, 915-929.
26. Gewirtz, G.R., Gorman, J.M., Volavka, J., Macaluso, J., Gribkoff, G., Taylor, D.P., Borison, R., 1994. Neuropsychopharmacology 10, 37-40.
27. 1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur. J. Pharmacol. 154, 339-341.
28. Goff, D.C., Midha, K.K., Brotman, A.W., McCormick, S., Waites, M., Amico, E.T., 1991. An open trial of buspirone added to neuroleptics in schizophrenic patients. J. Clin. Psychopharmacol. 11, 193-197.
29. 1A receptors in rat brain membranes. Eur. J. Pharmacol. 288, 173-186.
30. 1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur. J. Pharmacol. 211, 211-219.
31. Gudermann, T., Kalkbrenner, P., Schultz, G., 1996. Diversity and selectivity of receptor-G-protein interaction. Annu. Rev. Pharmacol. Toxicol. 36, 429-459.
32. 2 dopamine receptors. Br. J. Pharmacol. 121, 731-736.
33. 1A antagonist, WAY 100,635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology 127, 245-254.
34. Harvey, K.V., Balon, R., 1995. Augmentation with buspirone: a review. Ann. Clin. Psychiatry 7, 143-147.
35. 1A receptors in prefrontal cortex and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48, 355-363.
36. Jain, A.K., Kelwala, S., Moore, N., Gershon, S., 1987. A controlled clinical trial of tiaspirone in schizophrenia. Int. Clin. Psychopharmacol. 2, 129-133.
37. 3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe. Eur. J. Pharmacol. 329, 99-106.
38. Kenakin, T., 1996. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 48, 413-463.
39. 1A receptors. Eur. J. Pharmacol. 260, 79-83.
40. 1A receptor. J. Biol. Chem. 266, 23689-23697.
41. Maes, M., Meltzer, H.Y., 1995. The serotonin hypothesis of major depression. In: Bloom, F.E., Kupfer, D.J., (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, NY, pp. 933-944.
42. 1A receptors in human brain tissue. Eur. J. Pharmacol. 221, 397-398.
43. McMillen, B.A., Scott, S.M., Davanzo, E., 1988. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharm. Pharmacol. 40, 885-887.
44. 1A agonists. Mol. Pharmacol. 37, 231-237.
45. Meltzer, H.Y., 1996. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br. J. Psychiatry 168, 23-31.
46. 1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine 1C/2 receptors. J. Pharmacol. Exp. Ther. 262, 451-463.
47. 1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively. Eur. J. Pharmacol. 230, 99-102.
48. 1A antagonists. J. Pharmacol. Exp. Ther. 268, 337-351.
49. 2 receptors, and an atypical antipsychotic profile in the rat. Br. J. Pharmacol. 114, 156P.
50. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 275, 885-898.
51. 3 receptor antagonist, (+)S 14297, blocks the cataleptic properties of haloperidol in rats. Eur. J. Pharmacol. 321, R7-R9.
52. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and potential antidepressant properties. J. Pharmacol. Exp. Ther. 282, 132-147.
53. 1A receptor in rat hippocampus. Brain Res. 590, 229-238.
54. Moore, N.C., Meyendorff, E., Yeraggani, V., LeWitt, P.A., Gershon, S., 1987. Tiaspirone in schizophrenia. J. Clin. Psychopharmacol. 7, 98-101.
55. 1A 5-hydroxytryptamine receptors in Chinese Hamster Ovary cells. Biochem. J. 285, 933-938.
56. 35S]-GTPγS binding. Am. Soc. Neurosci. 21, 727.20.
57. 1A receptors. Neuropharmacology 35, 119-121.
58. 1A receptors. Eur. J. Pharmacol. 307, 107-111.
59. 1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br. J. Pharmacol. 120, 737-740.
60. 4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J. Pharmacol. Exp. Ther. 282, 181-191.
61. 1A receptor-mediated activation of high-affinity GTP hydrolysis in rat hippocampal membranes. J. Pharmacol. Exp. Ther. 274, 337-344.
62. 1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells. Biochem. Pharmacol. 45, 375-383.
63. 1A receptors and differential coupling to second messengers in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 346, 127-137.
64. sα. Biochemistry 32, 11064-11073.
65. 1A receptor activation. Eur. J. Pharmacol. 338, R3-R5.
66. Roth, B.L., Meltzer, H.Y., Khan, N., 1998. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv. Pharmacol. 42, 482-485.
67. 3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275, 1239-1246.
68. 1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br. J. Pharmacol. 95, 975-985.
69. Schotte, A., Janssen, P.F.M., Gommeren, W., Luyten, W.H.M.L., Van Gompel, P., Lesage, A.S., De Loore, K., Leysen, J.E., 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73.
70. 1A receptor antagonists. Eur. J. Pharmacol. 271, 537-541.
71. Schwartz, J.T., Brotman, A.W., 1992. A clinical guide to antipsychotic drugs. Drugs 44, 981-992.
72. Seeger, T.F., Seymour, P.A., Schmidt, A.W., Zorn, S.H., Schultz, D.W., Lebel, L.A., McLean, S., Guanowsky, V., Howard, H.R., Lowe, J.A., Heym, J., 1995. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275, 101-113.
73. 4 receptors. Neuropsychopharmacology 16, 93-110.
74. Sovner, R., Parnell-Sovner, N., 1989. Use of buspirone in the treatment of schizophrenia. J. Clin. Psychopharmacol. 9, 61-62.
75. 35S]GTPγS binding. Eur. J. Pharmacol. 320, 267-275.
76. 3H]spiperone discriminates between the G-protein-coupled and uncoupled forms. Biochem. Pharmacol. 45, 1003-1009.
77. 1D receptor subtypes. J. Recept. Signal Transduct. Res. 15, 199-211.
78. Tollefson, G.D., Sanger, T.M., 1997. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 154, 466-474.
79. Tran, P.V., Dellva, M.A., Tollefson, G.D., Beasley Jr., C.M., Potvin, J.H., Kiesler, G.M., 1997. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiatry 58, 205-211.
80. 1A receptors to adenylyl cyclase. Mol. Pharmacol. 41, 999-1007.
81. 1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol. Pharmacol. 41, 1066-1072.